A B S T R A C T Digitalis is known to have a vasoconstrictor effect in the coronary circulation. Recent studies have demonstrated that the coronary vasoconstrictor effects of acetylstrophanthidin and digoxin are neurally mediated via alpha adrenergic fibers. In the present study, experiments were done in 20 dogs anesthetized with chloralose and urethane to study the central nervous system as a possible site of action for this vasoconstrictor effect of digoxin. After the intravenous administration of 1.0 mg digoxin, cerebrospinal fluid concentrations of digoxin rose to a peak of 2.3±0.4 (SEM) ng/ml at 15 min, temporally corresponding to the peak in coronary vascular resistance change of + 20.0± 2.5% of control in the paced canine heart. Submicrogram digoxin injections into the lateral cerebral ventricle produced a significant increase in coronary vascular resistance, the latter injection producing a peak increase in coronary vascular resistance of 12.4±11.2% of control. Cross-perfusion experiments, where the isolated head of the operative dog was perfused from a donor dog receiving digoxin, thus keeping digoxin levels in the remainder of the operative dog very low, showed a similar degree of coronary vasoconstriction. Thus, the central nervous system appears to be an important site of action for the early coronary vasoconstrictor effect of digoxin.
INTRODUCTION
Digitalis has been known to have a constrictor effect in several vascular beds (1) (2) (3) . Vatner , Higgins, Franklin, and Braunwald extended these observations to the coronary vascular bed and demonstrated a ouabain-induced coronary vasoconstriction in conscious dogs (4) . Until A preliminary report of this work was presented at the 57th Annual Meeting of the Federation of American Societies for Experimental Biology (Fed. Proc. 1973. 32: 718. (Abstr.)
Received for publication 17 October 1973 and in revised form 13 August 1974. recently, it had been thought that a direct action of digitalis on vascular smooth muscle was the major cause of this vasoconstrictor effect (1, 3) . Nerve recordings, however, have provided evidence that the digitalis glycosides exert significant effects on the afferent and efferent autonomic nervous system (5) (6) (7) . Recent studies in our laboratory have demonstrated that the greatest portion of digoxin-induced coronary vasoconstriction and of acetylstrophanthidin-induced vasoconstriction in skeletal muscle is neurogenically mediated and occurs through stimulation of alpha adrenergic receptors (8, 9) . This effect appears to be due to the action of digitalis at or proximal to the sympathetic ganglia.
The present study was undertaken to determine the site of action of the coronary vasoconstrictor effect of digoxin. Specifically, the central nervous system (CNS )1 was investigated as a likely locus at which cardiac glycosides act to bring about this vasoconstrictor effect.
METHODS
20 mongrel dogs weighing between 18 and 22 kg were anesthetized with intravenous chloralose (60 mg/kg) and urethane (600 mg/kg). After the induction of anesthesia, an endotracheal tube was inserted. The animals were ventilated with a Harvard positive pressure respirator (Harvard Apparatus Co., Inc., Millis, Mass.) with 100% oxygen. Similarly anesthetized donor dogs were exsanguinated from one femoral artery. 50-100 cm8 of sodium bicarbonate (44 meq/50 cm8) and 20 cm' of heparin (1,000 U/cm') were added to the collected blood of the donor dog, and this blood was used when necessary in some experiments as described below.
In animals undergoing surgery, a right thoracotomy was performed. Care was taken during the surgical procedure to avoid damage to the neural supply (both sympathetic and vagal) to the heart. Coronary blood flow was measured by cannulating the coronary sinus by the method described by Gregg and Fisher (10) . After the thoracotomy, a wide-bore 'Abbreviations used in this paper: CNS, central nervous system; CSF, cerebrospinal fluid; LV dp/dt, first derivitive of left ventricular pressure with respect to time. (Bardic #16, Bard Parker Co., Inc., Div. Becton, Dickinson & Co., Danbury, Conn.) cannula was inserted through the right atrial appendage and ligated in place in the most distal end of the coronary sinus. Care was taken to assure that there was no occlusion of the small venous tributaries emptying into the coronary sinus near the right atrium (Fig. 1) . The cannula was held in a horizonal position by a brace, thus preventing motion that might lead to transient occlusion of these small tributaries. The distal end of this cannula was connected to a short rigid T-tube placed at the level of the right atrium. The lower arm of the T-tube drained freely, and the upper arm remained open to air. Although coronary venous pressure was not measured, in a previous study (9) coronary sinus pressure was monitored and remained constant (within 1 cm H20 of the control value) after the intravenous injection of 1.0 mg of digoxin. The control values were always between +1 and -3 cm H20. Coronary sinus outflow, a close approximation of total coronary blood flow, was quantitated by direct 1-min collections of the venous blood in a graduated cylinder. Although a small percentage of coronary blood flow is returned directly to the left ventricle via the Thebesian system, it seems unlikely that the results observed could be due entirely to the redistribution of coronary blood flow to the Thebesian system. To maintain systemic blood pressure constant, blood from the femoral artery of the dog was allowed to overflow into a cardiotomy funnel as shown in Fig. 1 . The volume that overflowed into the funnel was returned to the dog via the femoral vein at a constant rate by the use of a roller pump. The pump was automatically stopped by a photoelectric cell when the blood in the funnel fell below a certain level. The pump restarted when the volume accumulated above this level. This assured a near constant blood volume in the operative dog despite possible changes in venous capacitance. A tendency toward a slight increase or a slight decrease in the dog's systemic blood pressure resulted in an increase or a decrease in overflow and thus, a near constant systemic blood pressure. In several dogs in which the systemic pressure fell below the level of overflow toward the end of the experiment, blood from a donor dog was added to keep the systemic pressure stable.
The heart of the operative animal was paced with a Medtronic Model 5837 atrioventricular (Medtronic, Inc., Minneapolis, Minn.) to keep the heart rate and atrioventricular interval constant throughout each experiment. The pacing electrodes were sutured onto the epicardial surface of the right atrium and of the right ventricle, and atrioventricular sequential pacing was employed. In each experiment a pacing rate slighty above the intrinsic rate of the dog was chosen to assure consistent atrioventricular capture.
A rigid wide-bore cannula, inserted into the apex and sutured in place, was used to measure left ventricular systolic and end-diastolic pressures. Arterial pressure was measured in the brachial artery and central venous pressure in the superior vena cava. All pressures were recorded with Statham P23Db pressure transducers (Statham Instruments, Inc., Oxnard, Calif.). The electrocardiogram, arterial blood pressure, left ventricular pressure, left ventricular end-diastolic pressure, first derivative of left ventricular pressure with respect to time (LV dp/dt), and central venous pressure were recorded on a Sanborn Model 350 oscillograph (Hewlett-Packard Co., Waltham Div., Waltham, Mass.). LV dp/dt was obtained by resistance capacitor electronic differentiation of the full left ventricular pressure. Calibration of the dp/dt differentiator was accomplished by supplying a wave form of known slope to the differentiating circuit, which has a time constant of 0.001 s and a cutoff of 160 (11, 12) . CSF samples were obtained via a 20-gauge spinal needle inserted into the cisternum magnum posteriorly. The sample size was 0.3-0.5 cm8. To each sample was added 0.5 ml of plasma, and the total volume was brought to 1.0 ml, if necessary, by addition of buffered saline (150 mM sodium chloride, 10 
Experimental procedures
Injection of digoxin into CSF. In nine dogs a hole was drilled on the coronal suture of the skull 1 cm lateral to the sagittal sinus. The tip of a 20-gauge spinal needle was advanced into a cerebral ventricle through this hole. Another 20-gauge spinal needle was placed in the cisternum magnum. In seven dogs 0.1 ,gg (100 ng) of digoxin (Lanoxin, Burroughs Wellcome & Co., Inc., Tuckahoe, N. Y.) in 0.1 ml of modified Krebs-Ringers solution (143 mM sodium, 4.0 mM potassium, 2.5 mM calcium, 1.3 mM magnesium, 1.3 mM phosphate, 126 mM chloride, 25 mM bicarbonate. and 5.5 mM glucose), pH 7.35, was injected into the cerebral ventricle via the first needle and flushed with 0.9 ml of the same buffer. The cisternal needle drained freely during the injection. Digoxin determinations could be carried out on CSF samples subsequently obtained via the cisternal needle. By this method the drug was injected in the direction of physiological flow of CSF. Control injections into a cerebral ventricle of 1.0 ml of vehicle (propylene glycol 40%, ethanol 10%, and a sufficient quantity of water for injection in 0.1 ml of modified KrebsRinger solution) and flush solution alone preceded the administration of digoxin. Control injections of the vehicle alone resulted in less than a 1-2% change in coronary vascular resistance and the associated hemodynamics during a 20-min follow-up period. In each of two additional animals the control solution (vehicle and flush) was injected twice at 20-min intervals and coronary vascular resistance was calculated at 1 and subsequently at 5-min intervals for up to 1 h after the second injection.
Cross-head perfusion. In seven dogs all structures were sectioned across the neck at the level of C4 except the vagus nerve and the vertebral column and its contents. In the operative dog both common carotid arteries (just below the carotid sinuses) and both vertebral arteries were cannulated. These received blood from the femoral arteries of a support dog. Venous blood from the superior vena cava of the operative dog was returned to the support dog via the femoral veins of the latter. The operative dog was monitored from the catheter connecting the femoral arteries of the support dog to the carotid arteries immediately adjacent to the head of the operative dog. This remained stable throughout each experiment. After the termination of surgery and at the end of the experiment, intactness of autonomic nervous supply of the heart was tested by the response to carotid artery clamping.
In six dogs digoxin in a dose of 1.0 mg was administered intravenously to the support dog. Coronary blood flow of the operative dog was serially measured as described above.
Simultaneous arterial blood samples were obtained from both dogs at fixed time intervals after the injection to allow determination of plasma digoxin concentrations. In an additional dog a similar protocol was followed but 1 FIGURE 4 Coronary vascular resistance of the operative dog in a cross-perfusion preparation after injection of digoxin (1.0 mg i.v.) into the support dog. The middle panel shows the plasma digoxin levels in the support and operative dogs. Note the sustained increase in coronary vascular resistance in the operative dog despite very low (< 0.50 ng/ml) plasma digoxin levels.
which had a peak value of + 12.4±1.2% of control (Fig. 3) . The effect was significant (P <0.04) from 25 through 35 min. The mean control resistance was 1.2±0.1 mm Hg/cm/min. Table I summarizes the mean hemodynamic data from these seven dogs. Mean aortic pressure, pulse pressure, peak left ventricular pressure, peak LV dp/dt, left ventricular end-diastolic pressure, and central venous pressure remained stable. Heart rate was maintained constant for each experiment. Thus, there was no change in the hemodynamic correlates of myocardial oxygen consumption.
CSF digoxin concentrations were measured in five of the seven dogs. The mean values obtained in cisternal CSF samples after injection into the cerebral ventricles are included in Table I . The peak levels exceeded CSF digoxin concentrations obtained by the injection of 1.0 mg digoxin i.v., but the decline in these levels was more rapid. This decline presumably reflects the flow of CSF as well as uptake by CNS tissues.
In each of two additional dogs two control injections of the vehicle alone were made into the CSF at 20-min intervals. A 1 h followup period after the second injection revealed little change in coronary vascular resistance. In one animal the changes in resistance ranged between -8.5 and -3.5% of the control level. In the other animal the changes ranged between -4.4 and + 3.9% of the control level.
Cross-head perfusion. In five experiments out of six in which the cerebral circulation of the operative dog was supplied by arterial blood from the support dog, coronary vascular resistance increased after 1.0 mg of digoxin injected intravenously into the support dog. Data from a representative experiment are illustrated in Fig. 4 . The upper panel shows the increase in coronary vascular resistance, which peaked at a value of + 22% of control 30 min after intravenous administration of digoxin to the support dog. Control resistance was 0.6 mm Hg/cm/min. Fig. 4 also shows the mean arterial pressure and the plasma digoxin concentrations in the operative and support dogs. There was very little mixing between the two circulations, as judged by plasma digoxin levels in the operative dog, which remained less than 0.5 ng/ml throughout the experiment.
The data for coronary vascular resistance, coronary blood flow, and mean arterial pressure from the six experiments are shown in Table IL This table summarizes the experimental data from cross-head perfusion experiments in each of six dogs. In the control period before the administration of digoxin, five vascular resistance determinations, each at 5-min intervals, were within 3% of each other.
there was no increase in coronary vascular resistance, but coronary flow decreased by a small amount. In four of the five animals observed for more than 40 min, coronary resistance fell below the control level, thus raising the possibility of a second site of action of digoxin in the head and neck with opposing effects and a different time course of action. Also shown in Table II are the mean plasma digoxin concentrations of the operative and support dogs. To show that coronary vasoconstriction could not be caused by the low systemic digoxin concentrations observed in the operative dogs, a control cross-perfusion experiment was done in which the operative dog received 0.1 mg digoxin intravenously. This dose produced plasma digoxin levels comparable to or greater than those observed in the operative dogs, but coronary vascular resistance did not increase during the 30-min period after the injection. In an additional experiment 1.0 mg of digoxin was injected intravenously into the body of a head-perfused animal and except for a small, initial transient increase in coronary vascular resistance to 4% above control 5-min after the injection, vascular resistance at 5-mim intervals remained between -1 and -5.6% of control throughout 1 h after injection. In the support animal coronary vascular resistance was consistently at or below the control levels throughout the followup period. These findings were accompanied by operative dog serum digoxin levels of 190, 157, 85, 64, and 48 ng/ml at 5, 10, 20, 30, and 50, min after the in.
jection. Support dog serum digoxin levels collected at comparable times were consistently less than 0.1 ng/ml. DISCUSSION These data provide direct evidence that the CNS is a major site of action of digitalis in producing neurogenic vasoconstriction in coronary vasculature. The study clearly illustrates that this CNS effect of digoxin occurs independent of direct stimulation of receptors in either the peripheral afferent or efferent autonomic nervous system. Furthermore, the data establish that the neurogenic vasoconstrictor effect of digoxin on the coronary vasculature is independent of a possible reflex response to the associated hemodynamic effects of digitalis.
The close temporal correlation of the increase in CSF levels of digoxin with its neurogenic coronary vasocontrictor effect after intravenous injection suggests a causeand-effect relationship. (18) (19) (20) (21) (22) (23) , but a clinically important role has not generally been ascribed to them. Hamlin et al. (9) demonstrated that coronary vasoconstriction caused by intravenous digoxin could be abolished completely by previous alpha adrenergic receptor blockade with phenoxybenzamine or by ganglionic blockade with mecamylamine. This latter study also demonstrated that an associated decrease in myocardial oxygen consumption could not account for the observed vasoconstrictor effect of digoxin, thus clearly establishing that the mechanism of the neurogenic vasoconstrictor effect of digitalis is through alpha adrenergic receptor stimulation.
The present data do not allow a precise localization of the site of action of digoxin within the CNS in producing neurogenic vasoconstriction. Injection of digoxin into the lateral ventricles produced a rise in coronary vascular resistance that was more gradual than that achieved with the intravenous injection of the drug and did not reach substantial elevations until a later time after the injection. It is of interest in this regard that Gillis (6) has demonstrated that the increase in efferent sympathetic nerve firing associated with intravenous ouabain administration in the cat is still present after midbrain section, suggesting that the site of action of ouabain in their experiments was at the level of the brain stem.
The present study also provides data on the kinetics of digoxin transit across the blood-brain barrier. Digoxin, a relatively nonpolar compound, enters the CSF rapidly and is detected within the first 2 min after in-travenous injection. Digoxin levels in the CSF continue to rise until 15 min after injection and then slowly decline. Maximum concentrations free in the CSF in the present experiments were of the order of 3 X 10' M, and effective concentrations at CNS tissue receptors may have been substantially higher. This demonstration of the ability of digoxin to cross the blood-brain barrier suggests the relevance of continuing investigation of its effects on the CNS.
The CNS-mediated neurogenic vasoconstrictor effect of digoxin described in this study may have important clinical implications. For example, the vasoconstriction occurring soon after the intravenous administration of this cardiac glycoside is seen at a time that corresponds to the clinical observation of ventricular tachyarrhythmias (24) and the sporadically reported occurrence of angina pectoris (25) and pulmonary edema (24, 26) . These deleterious side effects of digoxin could be related at least in part to the neurogenic vasoconstrictor effect of the drug on the coronary and/or peripheral circulation. An evaluation of the neurogenic vascular resistance effects of cardiac glycosides against a background of varying levels of sympathetic activity and congestive heart failure remains to be carried out, both in the physiology laboratory and at the bedside.
